Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
- Conditions
- Interventions
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Julia Brown
- Target Recruit Count
- 122
- Registration Number
- NCT01295151
- Locations
- 🇬🇧
Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT01283971
Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Keio University
- Target Recruit Count
- 40
- Registration Number
- NCT01270035
- Locations
- 🇯🇵
Saitama Medical Center, Kawagoe, Saitama, Japan
🇯🇵Keio University Hospital, Shinanomachi, Tokyo, Japan
The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2011-01-05
- Lead Sponsor
- Skane University Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT01270087
- Locations
- 🇸🇪
Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Abbott
- Target Recruit Count
- 100
- Registration Number
- NCT01231321
- Locations
- 🇷🇺
Site Ref # / Investigator 17682, Kazan, Russian Federation
🇷🇺Site Ref # / Investigator 18081, Saint Petersburg, Russian Federation
🇷🇺Site Ref # / Investigator 17681, Moscow, Russian Federation
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT01225393
Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab
- Conditions
- Interventions
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 70
- Registration Number
- NCT01197144
- Locations
- 🇸🇪
Dep of Rheumatology, Stockholm, Sweden
🇸🇪MR Centre, Dep of Clinical Neuroscience, Stockholm, Sweden
Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea
- Conditions
- Interventions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2011-10-28
- Lead Sponsor
- Innovaderm Research Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01181570
- Locations
- 🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada
Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Regionshospitalet Silkeborg
- Target Recruit Count
- 30
- Registration Number
- NCT01174186
- Locations
- 🇩🇰
Regional Hospital of Silkeborg, Silkeborg, Denmark
🇩🇰Department of Rheumatology U, Aarhus Hospital, Aarhus, Denmark
🇩🇰Regional Hospital of Horsens, Department of Medicine, Horsens, Denmark
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 424
- Registration Number
- NCT01148225
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.